The average cost basis for U.S. spot Bitcoin ETF holders is estimated at $81,722, marking the price level where the average ETF position would return to a loss. Bitcoin recently rose above this level for the first time since January, signaling a break-even point for many holders. U.S. spot Bitcoin ETFs saw net inflows totaling $31 million on Sept. 28, with strong inflows from BlackRock and Grayscale funds. The market will watch ETF flows and Bitcoin's price action around $81,722 closely after key U.S. economic data releases on Sept. 30 to gauge investor sentiment and potential price direction.
Bitcoin ETF holders face an estimated loss threshold at $81,722, marking the average cost basis for U.S. spot Bitcoin ETFs. For readers following cryptocurrency markets, 17 out of 50 major cryptocurrencies on Pluang rose today while 32 fell. Notable movers include CRV at Rp6.972 with a 3.52% decline and a typical hold time of 62 days, as of Sep 30, 2026 14:51 WIB.
Near Protocol (NEAR) surged 3.04% within one hour to reach $5.05 on September 30, reflecting a 6.40% increase over the past 24 hours. This rise places NEAR among the top 21 cryptocurrencies by market capitalization, valued at about $6.58 billion. The...
Kodal Minerals PLC reported a £3.50 million profit for the first half of 2026, reversing a loss from the previous year, as its Bougouni lithium mine in West Africa completed its first full period of commercial production. The mine produced over 53,00...
Solana's price remains steady around $120, supported by 11 consecutive weeks of positive inflows into US-based spot Solana ETFs, totaling about $450 million in holdings. Last week alone, these ETFs attracted $188.21 million, the highest weekly inflow...
Bitcoin's market momentum has weakened as the share of supply held at a profit dropped to about 72%, down from a recent peak of 73.8% and below its long-term average of 76%. This decline occurred while Bitcoin's price hovered around $83,000 on Septem...
Ondine Biomedical has suspended trading to raise new investment following successful phase III trial results for its Steriwave nasal disinfection product, which reduced surgical site infections by 40.5%. The funds will support publishing trial result...
